LGMD2E is the most common type of sarcoglycanopathies in the Iranian population

Abstract Sarcoglycanopathies (SGCs) which are caused by mutations in SGCA, SGCB, SGCG or SGCD genes are a subgroup of autosomal-recessive limb-girdle-muscular-dystrophies (LGMD2). Although frequencies of mutations in these genes are different among populations, mutations in SGCA and SGCD, respectively, have the highest and lowest frequencies in most populations. Here, we report the proportion of mutations in SGC genes among a group of Iranian SGCs patients. Clinical features and results of SGC genes screening of 25 SGCs probands are presented. Large deletion mutations are confirmed with MLPA assays. In total, 15 candidate disease causing mutations were observed in the SGCA, SGCB, SGCG and SGCD genes; ten were novel. Fourteen (56%), seven (28%), three (12%) and one (4%) patient, respectively, carried mutations in SGCB, SGCG, SGCD and SGCA. The findings suggest that LGMD2E is the most common form of SGCs in the Iranian population and that LGMD2D is the rarest. Twelve LGMD2E cases carried the same mutation. To the best of knowledge, the mutation spectrum in SGCs is being reported for the first time in Iranian population. The finding will be beneficial for screening and genetic-counseling of SGCs patients in Iran.

[1]  C. Angelini,et al.  Pathogenesis, clinical features and diagnosis of sarcoglycanopathies , 2016 .

[2]  S. Zeinali,et al.  A novel mutation in alpha sarcoglycan gene in an Iranian family with limb girdle muscular dystrophy 2D , 2016, Neurological research.

[3]  A. Kariminejad,et al.  Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population , 2016, Clinical genetics.

[4]  S. Zeinali,et al.  A rare form of limb girdle muscular dystrophy (type 2E) seen in an Iranian family detected by autozygosity mapping , 2016, Journal of neurogenetics.

[5]  E. Pegoraro,et al.  Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E , 2015, Neurology.

[6]  Xin-mei Jiang,et al.  Limb-girdle muscular dystrophies: Where next after six decades from the first proposal (Review) , 2014, Molecular medicine reports.

[7]  P. Karimzadeh,et al.  Evaluation of One Hundred Pediatric Muscle Biopsies During A 2-Year Period in Mofid Children And Toos Hospitals , 2013, Iranian journal of child neurology.

[8]  K. Bushby,et al.  Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. , 2009, Brain : a journal of neurology.

[9]  M. Hegde,et al.  Spectrum of mutations in sarcoglycan genes in the Mumbai region of western India: high prevalence of 525del T. , 2009, Neurology India.

[10]  G. Dekomien,et al.  Detecting copy number variations in autosomal recessive limb-girdle muscular dystrophies using a multiplex ligation-dependent probe amplification (MLPA) assay. , 2009, Molecular and cellular probes.

[11]  K. Bushby,et al.  Sarcoglycanopathies: Can muscle immunoanalysis predict the genotype? , 2008, Neuromuscular Disorders.

[12]  F. Leturcq,et al.  Revised spectrum of mutations in sarcoglycanopathies , 2008, European Journal of Human Genetics.

[13]  D. MacArthur,et al.  Limb–girdle muscular dystrophy: Diagnostic evaluation, frequency and clues to pathogenesis , 2008, Neuromuscular Disorders.

[14]  R. Borgohain,et al.  Sarcoglycanopathies: a clinico-pathological study. , 2007, Neurology India.

[15]  A. Pestronk,et al.  Limb-Girdle Muscular Dystrophy in the United States , 2006, Journal of neuropathology and experimental neurology.

[16]  C. Angelini,et al.  Novel sarcoglycan gene mutations in a large cohort of Italian patients , 2003, Journal of medical genetics.

[17]  D. Hilton‐Jones,et al.  The limb-girdle muscular dystrophies , 2003, Neurology.

[18]  M. Passos-Bueno,et al.  Genotype-phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations , 2003, Journal of medical genetics.

[19]  L Politano,et al.  Evaluation of cardiac and respiratory involvement in sarcoglycanopathies , 2001, Neuromuscular Disorders.

[20]  M. Passos-Bueno,et al.  Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G. , 1999, American journal of medical genetics.

[21]  C. Angelini,et al.  The clinical spectrum of sarcoglycanopathies , 1999, Neurology.

[22]  M. Passos-Bueno,et al.  A first missense mutation in the delta sarcoglycan gene associated with a severe phenotype and frequency of limb-girdle muscular dystrophy type 2F (LGMD2F) in Brazilian sarcoglycanopathies. , 1998, Journal of medical genetics.

[23]  E. Hoffman,et al.  Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. , 1997, Journal of medical genetics.

[24]  J. Beckmann,et al.  A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey , 1997, Annals of neurology.

[25]  C. de Toma,et al.  Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). , 1997, Journal of medical genetics.

[26]  K. Campbell,et al.  Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. , 1997, Neurology.

[27]  E. Hoffman,et al.  Mutations in the sarcoglycan genes in patients with myopathy. , 1997, The New England journal of medicine.

[28]  L. Kunkel,et al.  Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. , 1996, American journal of human genetics.

[29]  M. Passos-Bueno,et al.  Autosomal recessive limbgirdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ–sarcoglycan gene , 1996, Nature Genetics.

[30]  L. Kunkel,et al.  Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy , 1995, Science.

[31]  J. Beckmann,et al.  β–sarcoglycan: characterization and role in limb–girdle muscular dystrophy linked to 4q12 , 1995, Nature Genetics.

[32]  L. Kunkel,et al.  β–sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex , 1995, Nature Genetics.

[33]  A. Roses,et al.  Evidence for linkage disequilibrium in chromosome 13-linked Duchenne-like muscular dystrophy (LGMD2C) , 1995, American journal of human genetics.

[34]  I. Nonaka,et al.  The Frequency of Patients With 50-kd Dystrophin-Associated Glycoprotein (50DAG or adhalin) Deficiency in a Muscular Dystrophy Patient Population in Japan , 1995, Neurology.

[35]  J. Beckmann,et al.  Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy , 1994, Cell.

[36]  H. Lochmüller,et al.  Chapter 3 - Sarcoglycanopathies , 2011 .

[37]  M. Passos-Bueno,et al.  Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. , 1996, Nature genetics.

[38]  J. Vance,et al.  Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. , 1995, Science.